Multifunctional nanomedicine prototypes acting as prophylactics and virus-assisted targeted drug delivery vehicle (NANOPROV)

未满足的需求。病毒感染是一种全球性威胁，也是造成重大社会和经济负担的根源。具有高传染性和高死亡率的新病毒的出现和重新出现有增加的趋势。从过去的大流行病，如全球大流行的SARS-CoV-2中吸取的教训表明，需要大量投资来完善科学和技术，以开发新的早期治疗抗病毒药物。这些抗病毒药物应该基于一种插件技术，可以迅速重新用于治疗下一个快速传播的病毒，并成功地控制流行病。方法和市场。在不同的技术中，基于纳米颗粒的药物显示出高附加值，估计复合年增长率为22%。基于蛋白质的纳米药物估计有150亿美元的市场规模。NANOPROV将创造新的基于蛋白质的预防性纳米药物。主要目标群体（仅在联合王国就超过800万人）将是公务员和免疫功能低下的患者（例如癌症患者）以及需要初级保健的人。创新的解决方案和背景。NANOPROV将使用一种插入式纳米笼技术，我们已经申请了专利，并建立在有关抗病毒结合蛋白的可用数据基础上。它为早期治疗创造了概念验证的有效抗病毒预防性纳米笼。这种插入式技术可以通过基因工程进行快速修改，并重新用于制造预防性纳米笼，以对抗新的快速传播的病毒。该项目将产生概念验证产品，用于开发可吸入制剂和临床前试验。我们的插入式纳米笼技术是基于无处不在的铁存储蛋白的生命铁蛋白。这种天然存在的纳米笼蛋白具有生物相容性、安全性和稳定性，并且已经显示出用于制造其他治疗剂（例如疫苗）的可接受的安全性。NANOPROV是铁蛋白纳米笼专家与伦敦国王学院和英国卫生安全局（UKHSA）的抗菌治疗专家之间的独特合作。该团队在开发抗菌产品方面拥有丰富的经验，并与世界领先的吸入给药、制剂和制造专家以及生物制药公司合作。预期影响。NANOPROV将完善开发早期治疗蛋白质纳米药物的科学和技术。这种独特的专业知识和经验的交叉融合将创造出抗病毒纳米药物的原型和技术进步，以快速重新利用来对抗快速传播的新病毒。它将使我们有信心利用我们的纳米笼技术开发其他纳米药物，包括多价嵌合疫苗和多价抗癌免疫治疗药物。

Unmet need. Viral infections are a global threat and the source of substantial social and economic burden. There is an increasing trend in the emergence and re-emergence of new viruses with high infectivity and mortality rates. Lessons learned from past pandemics, e.g. the global pandemic of SARS-CoV-2, demonstrate that a substantial amount of investment is needed to refine the science and technology to develop new early treatment antivirals. These antivirals should be based on a plug-in technology to be rapidly repurposed for treating the next fast-spreading virus and successfully managing pandemics. Approach and market. Among different technologies, pharmaceuticals based on nanoparticles show a high added value with an estimated compound annual growth rate of 22%. Protein-based nanopharmaceuticals are estimated to have a market size of $ 15 billion. NANOPROV will create novel protein-based prophylactic nanomedicines. The primary target group (> 8 million individuals in the UK alone) will be public servants and immunocompromised patients (e.g. cancer patients) and those requiring primary care. Innovative solution and background. NANOPROV will use a plug-in nanocage technology we have patented and built upon available data regarding antiviral binding proteins. It creates proof-of-concept efficacious antiviral prophylactic nanocages for early treatment. The plug-in technology can be quickly modified using genetic engineering and repurposed to create prophylactic nanocages against a new rapidly spreading virus. The project will generate the proof of concept product for developing inhalable formulations and preclinical tests. Our plug-in nanocage technology is based on the ubiquitous iron-storage protein of life ferritin. This naturally occurring nanocage protein is biocompatible, safe and stable and has shown an acceptable safety profile for making other therapeutics, such as vaccines.Team and environment. NANOPROV is a unique collaboration between experts in ferritin nanocages and those in antimicrobial therapeutics working at King's College London and the UK Health Security Agency (UKHSA). The Team has extensive experience developing antimicrobial products and collaborates with world-leading experts in inhalation drug delivery, formulation, and manufacturing and with biopharmaceutical companies. Expected impact. NANOPROV will refine the science and technology for developing early treatment protein-based nanopharmaceuticals. This unique cross-fertilisation of expertise and experience will create prototype antiviral nanomedicines and technological advances for rapid repurposing to counter a fast-spreading new virus. It will generate confidence in using our nanocage technology to develop other nanomedicines, including multivalent mosaic vaccines and multivalent anti-cancer immunotherapeutics.